Quincy Bioscience
TINA.org investigated Quincy Bioscience’s marketing of its brain supplement Prevagen, and was involved as amicus curiae in two separate lawsuits filed against the company. To read more about those efforts, click here.
Brands
Featured
Prevagen Memory Study Falls Short
TINA.org, AARP and others file legal brief urging court to reverse dismissal of Prevagen case.
The Latest
5 Ad Trends to Be Wary of in 2020
CGI influencers are here.
Thinking about Taking a Supplement for Brain Health? Not So Fast
Brain experts say save your money.
Comment at FDA Public Meeting on Dietary Supplements
Comment made by TINA.org executive director, Bonnie Patten at the FDA’s public meeting on Responsible Innovation in Dietary Supplements held on May 16, 2019. Thank you for the opportunity to…
Prevagen Is Going to the Dogs
Second Circuit rules FTC/NY case against Prevagen can proceed.
2nd Circ. Saves FTC Oversight Of Red-Hot Memory Aid Sector
Jeff Overly, Law360
Don’t Fall for the ‘Memory’ Pills Targeting Baby Boomers
Emily Dreyfuss, WIRED
Clear-cut fraud? Quincy Bioscience faces a potentially ruinous lawsuit over memory claims
Marc Eisen, Isthmus
Marketers exploit the aged with unproven brain-health claims
Rick Schmitt, Newsweek
Memory supplement from jellyfish doesn’t work, FTC says
Herb Weisbaum, Komo News
Prevagen’s Fishy Memory Claims Under Fire by Federal Regulators
Five things you should know about the FTC, New York lawsuit against Prevagen.
Class-Action Tracker
Prevagen
False advertising class-action lawsuits filed against Quincy Bioscience regarding its marketing of Prevagen